Prtk stock price target

Stock: PRTK, Company: Paratek Pharma Inc, Description: Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. Omadacycline is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. Paratek Pharmaceuticals, Inc. [PRTK] Price Analysis: Next ... Jan 10, 2020 · Paratek Pharmaceuticals, Inc. [PRTK] has 33.88M shares outstanding, amounting to a total market cap of $145.35M. Its stock price has been found in the range of 2.66 to 7.39. At its current price, it has moved down by -41.95% from its 52-week high, and it …

In depth view into PRTK (Paratek Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. PARATEK PHARMACEUTICALS, INC. : PRTK Stock Price ... Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Paratek Pharmaceuticals, Inc. (PRTK) Stock Price, Quote ... Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Analysts Are Bullish on Top Healthcare Stocks: Revance ... See today’s analyst top recommended stocks >> Paratek Pharmaceuticals (PRTK) In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Paratek Pharmaceuticals, with a price target of $18.00.The company’s shares closed last Monday at $3.60.

Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development

Paratek Pharmaceuticals, Inc. [PRTK] Price Analysis: Next ... Jan 10, 2020 · Paratek Pharmaceuticals, Inc. [PRTK] has 33.88M shares outstanding, amounting to a total market cap of $145.35M. Its stock price has been found in the range of 2.66 to 7.39. At its current price, it has moved down by -41.95% from its 52-week high, and it … Analyst Ratings for Paratek Pharmaceuticals (PRTK) UPDATE: Paratek Pharmaceuticals (PRTK) PT Lowered to $26 at Guggenheim BofA/Merrill Lynch Starts Paratek Pharmaceuticals (PRTK) at Neutral BTIG Maintains Bullish View on Paratek Pharmaceuticals PRTK Stock Price & Charts | Paratek Pharmaceuticals

PRTK | Paratek Pharmaceuticals Inc. Analyst Estimates ...

Stock Price Forecast for PRTK: Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a  In depth view into PRTK (Paratek Pharmaceuticals) stock including the latest price, Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? 6 days ago Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences ( NASDAQ: NERV) and Paratek Pharmaceuticals (NASDAQ: PRTK) Tsao covers the Healthcare sector, focusing on stocks such as Crinetics  15 Mar 2020 Shareholders in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) had a terrible week, as shares crashed 37% to US$2.92 in Yet prior to the latest earnings, analysts had been forecasting revenues of US$83.2m and losses  View live PARATEK PHARMACEUTICALS INC chart to track its stock's price PRTK, 1D. Long. PRTK: PRTK - Bulls Almost Hit The Target PennyStock101  There may be differences between the Equity Summary Score analyst count and the number of underlying analysts listed. Due to the timing in receiving ratings  The average PRTK stock price target is 15.00 with a high estimate of 34.00 and a low estimate of 6.00. EPS 

PRTK - Paratek Pharmaceuticals Inc. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. Paratek Pharmaceuticals started at strong buy with $36 stock price target at Raymond James MarketWatch. Tuesday, April 04, 2017. 08:20 AM ET.

The stock’s 50 day moving average price is $3.84 and its 200 day moving average price is $3.76. Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Tuesday, February 25th. The specialty pharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.22. PRTK Key Stats | stockrow: Paratek Pharmaceuticals, Inc ... Selected key stats of Paratek Pharmaceuticals, Inc. (PRTK) including 10 year stock price and latest news. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. Paratek Pharmaceuticals (NASDAQ:PRTK) Upgraded at Zacks ...

Paratek Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. PRTK updated stock price target summary.

PRTK - Paratek Pharma Stock Analyst Ratings - Barchart.com Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. Historical Ratings The table shows the mean historical analyst recommendation for the current period, along with the previous 1, 2, and 3 periods. 2 Stocks That Are Just Getting Started: Valley National ... 1 day ago · Their price target on the stock stands at $6. Canaccord Genuity also rated PRTK as Initiated on January 02, 2019, with its price target of $14 suggesting that PRTK could surge by 78.6% from its current share price. Even though the stock has been trading at $2.99/share, analysts expect it to surge by 7.36% to reach $15.00/share. Paratek Pharmaceuticals Inc (PRTK) Lined Up for Potential ...

Paratek Pharmaceuticals Inc (PRTK) Lined Up for Potential ... Aug 23, 2017 · Overall PRTK has a Strong Buy analyst consensus rating. In the last ten months, the stock has received 6 Buy ratings. The average analyst price target of $39.40 translates into serious upside Checking the True Picture for Paratek Pharmaceuticals, Inc ... Apr 08, 2020 · Additionally, PRTK shares got another “Buy” rating from H.C. Wainwright, setting a target price of $22 on the company’s shares, according to the report published in November 23rd, 2018. On August 27th, 2018, BofA/Merrill Initiated an Neutral rating and increased its price target to $13.